SCHEMBL2269205

SCHEMBL2269205

O=C(/C=C/c1cccc(Cl)c1)Nc1cc(-c2ccccc2)ccc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP3A4 P08684 2/20 0.61
CYP2C19 P33261 2/20 0.61
TRPM2 O94759 5/20 0.60
LTB4R Q15722 2/20 0.60
TRPA1 O75762 1/20 0.56
EGFR P00533 2/20 0.55
MAOB P27338 2/20 0.55
MMP1 P03956 1/20 0.55
MMP2 P08253 1/20 0.55
MMP9 P14780 1/20 0.55
MAOA P21397 1/20 0.55
ACLY P53396 3/20 0.55
LMNA P02545 1/20 0.53
GRIK1 P39086 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269206 1.00 MEN1 (0.61) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2277736 0.95 TRPM2 (0.63) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2277734 0.95 TRPM2 (0.63) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL8059612 0.89 MEN1 (0.65) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL8059615 0.89 MEN1 (0.65) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2269335 0.89 TRPM2 (0.75) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2269338 0.89 TRPM2 (0.75) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2271618 0.88 TRPA1 (0.73) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2271620 0.88 TRPA1 (0.73) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2779090 0.87 MEN1 (0.79) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885NPC1 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.